Segments (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Product revenues		$ 22,848	$ 21,392	$ 38,334	$ 41,219
Revenue from services		1,908	2,153	3,977	4,123
Revenue from transfer of intellectual property		17,673	0	30,202	476
Operating (loss) income		(25,409)	(34,885)	(82,322)	(65,160)
Depreciation and amortization		4,152	4,027	7,685	7,591
Net loss from investment in investees		(804)	(370)	(2,565)	(2,426)
Total revenues		42,429	23,545	72,513	45,818
Assets	[1]	1,525,491		1,525,491		$ 1,267,664
Goodwill	[1]	289,607		289,607		224,292
United States
Segment Reporting Information [Line Items]
Total revenues		2,525	2,153	5,019	4,599
Ireland
Segment Reporting Information [Line Items]
Total revenues		19,376	0	31,480	0
Chile
Segment Reporting Information [Line Items]
Total revenues		8,698	7,852	15,150	15,136
Spain
Segment Reporting Information [Line Items]
Total revenues		4,920	5,666	8,857	11,815
Israel
Segment Reporting Information [Line Items]
Total revenues		5,942	6,307	10,155	10,853
Mexico
Segment Reporting Information [Line Items]
Total revenues		968	1,546	1,852	3,377
Other
Segment Reporting Information [Line Items]
Total revenues		0	21	0	38
Corporate
Segment Reporting Information [Line Items]
Revenue from services		60	60	120	120
Revenue from transfer of intellectual property		0	0	0	0
Operating (loss) income		(12,905)	(7,038)	(22,882)	(13,174)
Depreciation and amortization		27	24	46	48
Net loss from investment in investees		0	0	0	0
Assets		130,638		130,638		95,094
Goodwill		0		0		0
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating (loss) income		(746)	(674)	(1,281)	(1,163)
Pharmaceuticals | Operating Segments
Segment Reporting Information [Line Items]
Product revenues		22,848	21,392	38,334	41,219
Revenue from services		0	0	0	0
Revenue from transfer of intellectual property		17,673	0	30,202	285
Operating (loss) income		(4,660)	(20,368)	(42,584)	(36,941)
Depreciation and amortization		2,371	2,287	4,138	4,135
Net loss from investment in investees		(804)	(370)	(2,565)	(2,426)
Assets		1,290,366		1,290,366		1,064,498
Goodwill		238,642		238,642		173,327
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Revenue from services		1,848	2,093	3,857	4,003
Revenue from transfer of intellectual property		0	0	0	191
Operating (loss) income		(7,098)	(6,805)	(15,575)	(13,882)
Depreciation and amortization		1,754	1,716	3,501	3,408
Net loss from investment in investees		0	$ 0	0	$ 0
Assets		104,487		104,487		108,072
Goodwill		$ 50,965		$ 50,965		$ 50,965

[1] As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.